Items tagged with Drug-resistant TB
Clinical trial for drug-sensitive and drug-resistant TB regimen evaluated shorter regimens (SimpliciTB trial) (post)
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference. SimpliciTB was conducted to evaluate the BPaMZ regimen, consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). This combination previously showed high efficacy and treatment shortening potential in both preclinical evaluations and an early-stage clinical study in drug-resistant patients.
Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB (post)
SEATTLE, February 22, 2023 -- Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II study.
CROI 2023 TB research round up (post)
Treatment Action Group (TAG) released an overview of TB research data reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) held on 19-22 February 2023 in Seattle, Washington, USA. Highlights include the much-anticipated results of the SimpliciTB trial; additional analyses of the two-month TB treatment regimen studied in the TRUNCATE-TB trial; and the first clinical trial data on sutezolid since 2012.
RESIST-TB webinar: DR-TB drugs under the microscope (post)
RESIST-TB will host a webinar on 9 March 2023, Drug-resistant TB (DR-TB) drugs under the microscope. The speakers will present on pricing elements and intellectual property/licensing for DR-TB medicines.
MSF Science (@MSFSci) Twitter Spaces event - Treating drug-resistant TB: the past, present and future (post)
On Friday 24th March, the MSF Science Twitter account will be hosting a Twitter Spaces event (a live audio discussion) on ‘Treating drug-resistant tuberculosis: the past, present and future’!
RESIST-TB March 2023 newsletter (post)
RESIST-TB released its March 2023 newsletter with the latest updates and research publications on drug-resistant TB.
New TB vaccines needed to tackle AMR (post)
Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick, and poses catastrophic costs for patients and rising costs for health systems. The growing threat of drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths. New vaccines are urgently needed to tackle this crisis. Yet, despite the huge threat posed by drug-resistant TB, political and financial support falls dangerously short of what is needed to effectively address this threat.
Significant step in fight against drug resistance in TB (post)
University of Otago researchers have discovered new ways to treat antibiotic-resistant strains of tuberculosis (TB), opening the door to new approaches for tackling the disease that kills about 4,000 people a day.
Standigm and Institut Pasteur Korea identify lead compounds for resistant TB thanks to Right Foundation grant (post)
SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute Institut Pasteur Korea announced that they have jointly developed new lead compounds effective in treating resistant tuberculosis (TB). The two organizations conducted a technology acceleration grant project supported by the Right Foundation from 2021 to 2022. They achieved encouraging results by combining their core competencies of artificial intelligence (AI) platforms, infectious disease research capabilities and drug discovery technologies. This breakthrough demonstrates that AI technology can effectively address unmet medical needs for low and middle-income countries that tend to have higher than normal rates of resistant TB.
Progress in the fight against drug-resistant TB (post)
To mark World TB Day, RESIST-TB released an overview summarizing the past year's achievements, challenges, and continued progress in the fight against drug-resistant TB.
Page 79 of 117 · Total posts: 0
←First 78 79 80 Last→